ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Public ClinicalTrials.gov record NCT05746559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Study identification
- NCT ID
- NCT05746559
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 555 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 5, 2023
- Primary completion
- Oct 6, 2025
- Completion
- May 6, 2026
- Last update posted
- Jul 21, 2026
2023 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Orange | California | 92868 | — |
| Research Site | San Francisco | California | 94143 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Springfield | Massachusetts | 01107 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Rochester | New York | 14621 | — |
| Research Site | Valhalla | New York | 10595 | — |
| Research Site | Fargo | North Dakota | 58102 | — |
| Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Richmond | Virginia | 23298 | — |
| Research Site | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05746559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05746559 live on ClinicalTrials.gov.